Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q3 2018 Earnings Conference Call Transcript

Nov 06, 2018 • 04:30 pm ET


Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q3 2018 Earnings Conference Call Transcript


Loading Event

Loading Transcript


Good afternoon. And welcome to the Aquestive Therapeutics Third Quarter 2018 Conference Call. At this time, all participants are in a listen-only mode. Later, there will be a question-and-answer session, and instructions will be given at that time. (Operator Instructions) As a reminder, this call will be recorded.

I would now like to introduce your host for today's conference, Ms. Stephanie Carrington, ICR IR. You may begin.

Stephanie Carrington

Thank you, operator. Good afternoon. And welcome to today's conference call to review Aquestive Therapeutics results for the three months ended September 30, 2018. On this call, I am joined today by Keith Kendall, CEO; Ken Marshall, Chief Commercial Officer; Dan Barber, Chief Strategy and Development Officer; John Maxwell, CFO; and Lori Braender, General Counsel.

I trust that you have seen the press release that was issued this afternoon after market closed. It includes the results for the three months ended September 30, 2018, as well as an operational update. If you have not, the press release is also available on the IR portion of the Aquestive Therapeutics' website.

On today's call Keith will provide clinical and business highlights for the third quarter 2018, followed by Ken, who will provide the commercialization update, and Dan, who will provide a more in-depth review of the update of the proprietary product pipeline and the partner products. John will then review the company's financial results for the three months and nine months ended September 30, 2018. We will then open the call to your questions and expect this call to last approximately 60 minutes.

As a reminder, the conference call is being recorded and will be available on Aquestive Therapeutics' IR website shortly following the conclusion of today's call.

(Forward-Looking Cautionary Statements)

With that, I will now turn the line over to Keith.

Keith Kendall

Thank you, Stephanie. Thank you everyone for joining today's call. Let me take this opportunity to remind everyone that Aquestive is a fully integrated specialty pharmaceutical company committed to identifying, developing and commercializing differentiated products. Over the past few months, we have made significant strides in advancing our business on multiple fronts. To complement our ability to solve patient and caregiver problems, and our world-class manufacturing capabilities, we have assembled an experienced commercial team. This will better enable us to advance and commercialize products, and product candidates that leverage our differentiated PharmFilm technology.

We have continued to build out our commercial organization as we get set for the launch of our CNS products. We added sales and marketing expertise with experience in over 50 product launches. We continue to expand and strengthen our executive team to bring the needed skills and experience to grow and perform as a specialty pharmaceutical company. We added a General Counsel with extensive experience in the life sciences field as the Chair of the Life Sciences Practice Group.

We strengthened our Board of Directors as a public company by adding Nancy Lurker and naming Sandy Costa as Chairman. Sandy, who joined our board in 2015, brings over 40 years